Latest information on COVID-19
Support teaching, research, and patient care.
29 years of experience practicing general and geriatric psychiatry, and addiction medicine - inpatient, outpatient, emergency room, crisis residential, partial hospitalization, hospital consult, and telemedicine.Board Certified in Psychiatry, Geriatric Psychiatry, and in the new medical specialty of Addiction MedicineTrained hundreds of resident physicians and medical students in inpatient and emergency room psychiatry and addiction medicine23 years of experience as director of NIH-funded laboratory performing molecular biology and geneticsExtensive publication record in the neurobiology of Alzheimer’s disease, and in pharmacogenetics.Licensed to practice Medicine in California, Hawaii, Maryland, District of Columbia, and Virginia
Over the years my laboratory addressed scientific problems related to neuroscience, genetics, psychiatry, neurology and addiction medicine. Initially, we investigated expression of beta amyloid and related markers in Alzheimer’s disease brain. Simultaneously we developed cell culture models using astrocytes and microglia to investigate production of cytokines by glia, thus defining the inflammatory repertoire of these cells. Next, we began human genetics studies to assess the effect of the APOE epsilon 4 allele on clinical phenotypes in Alzheimer’s disease and other conditions. We then employed organotypic hippocampal explant cultures to study glial-neuronal interactions. This involved utilizing confocal microscopy to image cells in the 3-dimentional hippocampal cultures, as well as implementing PCR techniques for quantifying gene expression in minute volumes of tissue. Ultimately, we developed a microglia-hippocampal co-culture model with genetically engineered exogenous microglia to study cell-cell inflammatory processes. With this model we discovered novel effects of inflammatory cytokines on neurons. We also engineered endogenous microglia in the organotypic cultures using biolistics, to confirm results obtained in the co-cultures. We were early adopters of microarray technology for studying gene expression as well as for genotyping and DNA sequencing. We applied microarray approaches to gene expression in transgenic mouse models for Alzheimer’s disease, identifying a variety of markers induced by brain amyloid beta. Simultaneously, we were among the first to apply microarray technology to genotyping for markers for clinical medication response, adverse reactions, and metabolism. Finally, we performed large scale genotyping studies to identify markers for antidepressant response and response to medications for smoking cessation.
Genetics of Symptomatology and Treatment Response in Psychotic Major Depression
We hope to learn more about the biology of psychiatric illness with the hope of improving the
diagnosis and treatment of such psychiatric conditions as major depression.
Stanford is currently not accepting patients for this trial.
For more information, please contact Gregory H Cohen, MSW, 650-723-3305.
View full details